AbbVie: Alzheimer Disease trials

The registry lists 27 Alzheimer Disease studies with AbbVie as lead sponsor. 1 are open to participants now and 7 have results posted.

Phase 1 7Phase 2 16Phase 3 3Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's DiseaseRecruitingNCT07599670Phase 1/2
• Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's DiseaseCompletedNCT05771428Phase 2Results posted
• An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)TerminatedNCT03712787Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's DiseaseCompletedNCT02880956Phase 2Results posted
• A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's TypeCompletedNCT02549196Phase 2Results posted
• A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type DementiaCompletedNCT02185053Phase 2Results posted
• Effect of Memantine on Functional Communication in Patients With Alzheimer's DiseaseCompletedNCT00469456Phase 4Results posted
• A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's DiseaseCompletedNCT00322153Phase 3Results posted
• A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy ParticipantsCompletedNCT06406348Phase 1
• A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's DiseaseCompletedNCT05644977Phase 1
• A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's DiseaseCompletedNCT05291234Phase 2
• A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's DiseaseWithdrawnNCT03316898Phase 1
• CPC-201 Alzheimer's Disease Type Dementia: PET StudyWithdrawnNCT02860065Phase 2
• Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive ImpairmentTerminatedNCT02573740Phase 1
• Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07CompletedNCT02434666Phase 2
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsTerminatedNCT02220738Phase 1
• Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsCompletedNCT01908010Phase 1
• Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedNCT01690195Phase 2
• This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedNCT01676935Phase 2
• Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsCompletedNCT01549834Phase 2
• Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT01527916Phase 2
• Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's DiseaseCompletedNCT01137526Phase 2
• Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's DiseaseCompletedNCT01018875Phase 2
• Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's DiseaseCompletedNCT00948909Phase 2
• Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)CompletedNCT00334906Phase 4
• An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's DiseaseCompletedNCT00097916Phase 3
• The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's DiseaseCompletedNCT00090116Phase 3